Royalty Pharma RPRX NASDAQ · Healthcare · United States
$67.72 -1.38% -$0.95
Summary
53 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 162% a year over the last 3 years.
- Out of every 100 USD of revenue, 26 USD is left as net profit.
- It has raised its dividend 5 years in a row.
- It bought back its own shares for $1.23B in the last fiscal year, 4.0% of its market value.
What to watch
- Repaying its net debt would take 5.2 years of operating profit.
- You pay 45.5 USD for 1 USD of yearly profit, a lot for its sector.
- Revenue grew by only 2.1% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 45.5 USD for 1 USD of yearly profit. Over the last five years it was 98.3 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.3% a year over 5 years. Over the last 3 years it grew by 2.1% a year. Earnings per share grew by 162% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 13 USD
- Research and development 9.6 USD
- Sales and administration 18 USD
- Taxes and other 34 USD
- Net profit 26 USD
Net profit, industry median (Medical - Pharmaceuticals) 6.3 USD
Out of every 100 USD of revenue, 26 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.9 years of free cash flow. Its debt is larger than its cash. The debt score is low because of the debt-to-equity ratio (1.3x).
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.37%
- Paid out of profit
- 62%
- Raised in a row
- 5 years
You receive $0.94 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $66.5 is 1.8% below today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Financial Royalty Assets 95%
- Royalty Income, Other 4.9%
By region
The company reports no revenue by region.
Financial Royalty Assets brings in 95% of revenue. Royalty Income, Other grew fastest, by 22% a year.
Segments in detail